 |
|
Chinese Trial on Isolated Systolic Hypertension in the Elderly
Ji-Guang Wang, MD;
Jan A. Staessen, MD, PhD;
Lansheng Gong, MD;
Lisheng Liu, MD;
for the Systolic Hypertension in China (Syst-China) Collaborative Group
Arch Intern Med. 2000;160:211-220.
Background In 1988, the Systolic Hypertension in China (Syst-China) Collaborative Group initiated the placebo-controlled Syst-China trial to investigate whether antihypertensive drug treatment could reduce the incidence of fatal and nonfatal stroke in older Chinese patients with isolated systolic hypertension.
Objectives To explore (1) whether the benefits of active treatment were evenly distributed across 4 strata, prospectively defined according to sex and previous cardiovascular complications, and (2) whether the morbidity and mortality results were influenced by age, level of systolic or diastolic blood pressure (BP), smoking or drinking habits, or diabetes mellitus at enrollment.
Methods Eligible patients had to be 60 years or older with a sitting systolic BP of 160 to 219 mm Hg and diastolic BP less than 95 mm Hg. After stratification for center, sex, and previous cardiovascular complications, 1253 patients were assigned to active treatment starting with nitrendipine (10-40 mg/d), with the possible addition of captopril (12.5-50.0 mg/d), and/or hydrochlorothiazide (12.5-50 mg/d). In the 1141 control patients, matching placebos were used similarly.
Results Male sex, previous cardiovascular complications, older age, higher systolic BP or lower diastolic BP, living in northern China, smoking, and diabetes mellitus significantly and independently increased the risk of 1 or more of the following end points: total or cardiovascular mortality, all fatal and nonfatal cardiovascular end points, all strokes, and all cardiac end points. In the placebo-control group diabetes raised the risk of all end points 2- to 3-fold (P .05). However, active treatment reduced the excess risk associated with diabetes to a nonsignificant level (P values ranging from .12-.86) except for cardiovascular mortality (P = .04). Cox regression with adjustments applied for significant covariates suggested that active treatment may reduce total mortality more (P = .06) in women and stroke more (P = .07) in men and that it may provide better protection against cardiac end points in nonsmokers than smokers (P = .04). Otherwise, the benefits of active treatment were equally manifest, regardless of the enrollment characteristics of the patients, and regardless of whether active treatment consisted of only nitrendipine or of nitrendipine associated with other active drugs.
Conclusions In elderly Chinese patients with isolated systolic hypertension, stepwise antihypertensive drug treatment, starting with the dihydropyridine calcium channel blocker nitrendipine, improved prognosis. The benefit was particularly evident in diabetic patients; for cardiac end points it tended to be larger in nonsmokers. Otherwise, the benefit of active treatment was not significantly influenced by the characteristics of the patients at enrollment in the trial.
From the Hypertension Division, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China (Drs Wang and Liu); the Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium (Dr Staessen); and the Shanghai Hypertension Institute, Shanghai Second Medical University, Shanghai, People's Republic of China (Dr Gong).
RELATED ARTICLE
Benefits of Antihypertensive Therapy in Older Patients With Hypertension
William B. White
Arch Intern Med. 2000;160(2):149-150.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Stepwise increase in the prevalence of isolated systolic hypertension with the stages of chronic kidney disease
Cheng et al.
Nephrol Dial Transplant 2008;0:gfn383v1-gfn383.
ABSTRACT
| FULL TEXT
Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction
Thune et al.
Hypertension 2008;51:48-54.
ABSTRACT
| FULL TEXT
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J Suppl 2007;9:C3-C74.
FULL TEXT
Combining Multiple Approaches for the Secondary Prevention of Vascular Events After Stroke: A Quantitative Modeling Study
Hackam and Spence
Stroke 2007;38:1881-1885.
ABSTRACT
| FULL TEXT
Blood pressure and ageing
Pinto
Postgrad. Med. J. 2007;83:109-114.
ABSTRACT
| FULL TEXT
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J 2007;28:88-136.
FULL TEXT
Abnormal Pressure Passive Dilatation of Cerebral Arterioles in the Elderly With Isolated Systolic Hypertension
Castellani et al.
Hypertension 2006;48:1143-1150.
ABSTRACT
| FULL TEXT
Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Whelton et al.
Arch Intern Med 2005;165:1401-1409.
ABSTRACT
| FULL TEXT
Management of Hypertension in the Very Elderly Patient
Elliott
Hypertension 2004;44:800-804.
ABSTRACT
| FULL TEXT
Cerebral involvement in hypertensive cardiovascular disease
Coca
Eur Heart J Suppl 2003;5:F19-F25.
ABSTRACT
Treatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure Goals, Choice of Agents, and Setting Priorities in Diabetes Care
Vijan and Hayward
ANN INTERN MED 2003;138:593-602.
ABSTRACT
| FULL TEXT
Outcome beyond blood pressure control?
Staessen et al.
Eur Heart J 2003;24:504-514.
FULL TEXT
Resistant Hypertension: Comparing Hemodynamic Management to Specialist Care
Taler et al.
Hypertension 2002;39:982-988.
ABSTRACT
| FULL TEXT
Blood Pressure Control and Benefits of Antihypertensive Therapy: Does It Make a Difference Which Agents We Use?
Ruilope and Schiffrin
Hypertension 2001;38:537-542.
ABSTRACT
| FULL TEXT
The American Diabetes Association's 48th Annual Advanced Postgraduate Course
Bloomgarden
Diabetes Care 2001;24:1489-1495.
FULL TEXT
Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension
Kario et al.
J Am Coll Cardiol 2001;38:238-245.
ABSTRACT
| FULL TEXT
Prognostic Significance of Serum Creatinine and Uric Acid in Older Chinese Patients With Isolated Systolic Hypertension
Wang et al.
Hypertension 2001;37:1069-1074.
ABSTRACT
| FULL TEXT
Pulse pressure--a review of mechanisms and clinical relevance
Dart and Kingwell
J Am Coll Cardiol 2001;37:975-984.
ABSTRACT
| FULL TEXT
High Blood Pressure and Diabetes Mellitus: Are All Antihypertensive Drugs Created Equal?
Grossman et al.
Arch Intern Med 2000;160:2447-2452.
ABSTRACT
| FULL TEXT
Benefits of Antihypertensive Therapy in Older Patients With Hypertension
White
Arch Intern Med 2000;160:149-150.
FULL TEXT
|
